What is the global market size of the Platelet Rich Plasma Market?

Global Platelet Rich Plasma Market size was valued at USD 546.6 million in 2021 and is poised to grow from USD 629.19 million in 2022 to USD 2232.54 million by 2030, growing at a CAGR of 11.15% in the forecast period (2023-2030).

Platelet Rich Plasma Market Size

Platelet Rich Plasma Market Insights

Platelet Rich Plasma Market size was valued at USD 629.19 Million in 2023 and is poised to grow from USD 699.34 Million in 2024 to USD 2481.47 Million by 2032, growing at a CAGR of 11.15% during the forecast period (2025-2032).

Injections of platelet-rich plasma (PRP) are becoming more and more popular for treating a range of ailments, including hair loss and sports injuries. A patient's own blood cells are used in the procedure to hasten the healing of a particular area. Many musculoskeletal injuries and conditions may be treated with PRP injections. For instance, adding PRP injections to a treatment plan can help to speed up the healing process, lessen pain, and enable a quicker return to activities for chronic tendon injuries like tennis elbow or jumper's knee. Prospects for extensive medical study have been opened up by the growing use of platelet-rich plasma in surgical and regenerative therapy treatments. This will drive demand in the market along with an increase in the frequency of sports-related injuries, oral and maxillofacial procedures, and periodontal surgery.

US Platelet Rich Plasma Market is poised to grow at a sustainable CAGR for the next forecast year.

FAQs

Global Platelet Rich Plasma Market is moderately competitive. To maintain a competitive edge, the major industry participants are continually implementing various growth strategies. Innovations, mergers, and acquisitions, collaborations and partnerships are adopted by these players to thrive in the competitive market. Major Players include Johnson & Johnson, Arthrex, Inc., EmCyte Corporation and DR. PRP AMERICA, LLC. among others. In order to provide industries with the most effective and economical solutions, the major market players are also continually concentrating on R&D. 'Harvest Technology (USA) ', 'Stryker Corporation (USA) ', 'Zimmer Biomet (USA) ', 'Arthrex Inc. (USA) ', 'Terumo BCT Inc. (USA) ', 'Celling BioSciences Inc. (USA) ', 'APEX Biologix (USA) ', 'Juventix Regenerative Medical, LLC (Italy) ', 'Dr. PRP USA LLC (USA) ', 'Ycellbio Medical Co., Ltd. (South Korea) ', 'EmCyte Corporation (USA) ', 'Regen Lab SA (Switzerland) ', 'Zimmer Biomet (USA) ', 'Arthrex Inc. (USA) ', 'Terumo BCT Inc. (USA) ', 'Celling BioSciences Inc. (USA)'

The use of platelet-rich plasma in the treatment of orthopaedic diseases, musculoskeletal ailments, and sports injuries has seen a surge in demand. It focuses on growth factors and can speed up healing considerably. PRP is a significant source of personalised products for each patient in the field of regenerative medicine, supporting the cascade of wound healing and tissue restoration. These factors positively affect the market growth.

Human dermal cells that control hair follicle development are successfully multiplied by platelet-rich plasma. PRP has led to an overall rise in hair density, which is driving demand in the market both as a stand-alone treatment and in combination with hair transplant procedures. Given that PRP is an autologous product, it is thought to be safe and devoid of infectious infections. No major post-treatment adverse effects have been reported, however mild side effects including bruising, erythema, and crusting are thought to be rather prevalent. Researchers have discovered proof that PRP can stimulate fresh hair growth. To determine if PRP is efficient, however, further study is required because to the drawbacks of these trials, including as their small sample numbers and the variations in technique and procedure across physicians. The best PRP candidates must be found, and standardised treatment methods must be developed by medical professionals and researchers.

North America dominated the Global Platelet Rich Plasma Market share in 2021. This may be ascribed to the existence of several production facilities eager to create innovative PRP-based treatment methods, the high procurement at end-users including hospitals and clinics, and the presence of significant market participants. The market presence was reinforced by the assistance and approvals given by regulatory bodies. Such actions are predicted to increase market availability of platelet-rich plasma and speed up growth. During the projected period, it is predicted that the U.S. would provide promising growth opportunities. In the nation, PRP-based therapies are extensively used, with an increase in orthopaedic and aesthetic operations. The prominence of major players in the U.S together with the developed healthcare system in the nation, will also continue to influence the demand prognosis for platelet-rich plasma over the evaluation period. Due to these developments, the industry is anticipated to have a 3/10th market share.